What the FSGS Market Shift Means for Commercial Strategy
After decades with no approved therapy, the FSGS treatment landscape is changing within a compressed window. Travere’s Filspari (sparsentan) is newly approved by the FDA as of April 13, 2026, [...]
What We Can Expect from the Next Wave of ATTR-CM Therapies
A continued trend towards earlier diagnosis and the potential impact of monoclonal antibodies are anticipated to reshape the market Historically underdiagnosed, transthyretin amyloidosis (ATTR) and ATTR-cardiomyopathy (ATTR-CM) have become [...]
Systemic Lupus Erythematosus (SLE): A Market in Transition
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder marked by unpredictable organ involvement, clinical variability, and a high burden of chronic therapy. For biopharma teams evaluating opportunity in SLE, [...]
The Disease-Modifying Era in Angelman Syndrome
Why therapeutic window, and patient segmentation will become increasingly important in Angelman syndrome The Angelman syndrome (AS) treatment landscape is on the verge of a fundamental shift from symptomatic [...]
What the FSGS Market Shift Means for Commercial Strategy
After decades with no approved therapy, the FSGS treatment landscape is changing within a compressed window. Travere’s Filspari (sparsentan) is newly approved by the FDA as of April 13, 2026, [...]
What We Can Expect from the Next Wave of ATTR-CM Therapies
A continued trend towards earlier diagnosis and the potential impact of monoclonal antibodies are anticipated to reshape the market Historically underdiagnosed, transthyretin amyloidosis (ATTR) and ATTR-cardiomyopathy (ATTR-CM) have become [...]
Systemic Lupus Erythematosus (SLE): A Market in Transition
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder marked by unpredictable organ involvement, clinical variability, and a high burden of chronic therapy. For biopharma teams evaluating opportunity in SLE, [...]
The Disease-Modifying Era in Angelman Syndrome
Why therapeutic window, and patient segmentation will become increasingly important in Angelman syndrome The Angelman syndrome (AS) treatment landscape is on the verge of a fundamental shift from symptomatic [...]